Granulocyte collection using a novel apheresis system eases the procedure and provides concentrates of high quality. Issue 5 (21st November 2014)

• Record Type: Journal Article
• Authors: Leitner, Gerda C.; Kolovratova, Vera; Horvath, Michaela; Worel, Nina
• Is Part Of: Transfusion. Volume 55:Issue 5(2015)
• Page Start: 991
• Page End: 995
• Publication Date: 2014-11-21
• Subjects: Hematology -- Periodicals; Blood -- Transfusion -- Periodicals; Blood Group Antigens -- Periodicals; Blood Preservation -- Periodicals; Blood Transfusion -- Periodicals; 615
• DOI: 10.1111/trf.12928
• Languages: English
• ISSNs: 0041-1132

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="trf12928-sec-0001" sec-type="section"> <title>Background</title> <p>The latest technical innovation for granulocyte (PMN) collections is the fully automated Spectra Optia (Optia) device (TerumoBCT). In a retrospective investigation we evaluated the impact of the technical automation on the product quality in a routine working field.</p> </sec> <sec id="trf12928-sec-0002" sec-type="section"> <title>Study Design and Methods</title> <p>A total of 71 granulocyte collections (GCs) were collected from either routine random blood donors, mobilized with prednisolone (P; two females/23 males; median age, 42 years; range, 25‐63 years), or family donors (three females/12 males; median age, 29 years; range, 21‐59 years) who were mobilized with recombinant human granulocyte–colony‐stimulating factor (rHuG‐CSF) at a dose of 5 μg/kg body weight. All collections were performed with the Optia device. Fifty‐nine concentrates (GTX) produced with the Cobe Spectra (Cobe; TerumoBCT) served as a historical control.</p> </sec> <sec id="trf12928-sec-0003" sec-type="section"> <title>Results</title> <p>In total a mean of 452 ± 60 mL with a mean purity of 83 ± 9.6% PMNs was collected with the Optia. Compared with the Cobe collections (298 ± 52 mL), the product volumes in general as well as the absolute PMN yield in P‐mobilized products were significantly higher with the Optia: PMN count, 1.9 × 10<sup>10</sup> ± 0.49 × 10<sup>10</sup> versus 1.5 × 10<sup>10</sup> ± 0.85 × 10<sup>10</sup>, respectively (p < 0.05), due to higher white blood cell (WBC) yields. rHuG‐CSF–mobilized products showed no significant differences in the absolute WBC (7.2 ± 3.0/Optia vs. 7.0 ± 2.1/Cobe) and PMN (5.9 ± 2.6/Optia vs. 5.7 ± 1.9/Cobe) yield. The PMN purity was equal in both devices (mean, 83%) although it was slightly lower in the rHuG‐CSF group (82 ± 9.2%) than in the P group (84 ± 6.2%). In none of the procedures were side effects recorded.</p> </sec> <sec id="trf12928-sec-0004" sec-type="section"> <title>Conclusion</title> <p>GC with the fully automated Optia device is safe for donors, is not inferior to its forerunner Cobe Spectra, produces GTX of a high quality, and requires less manpower than the Cobe Spectra.</p> </sec> </abstract>